

<b>2.01.49 Transurethral Water Vapor Thermal Therapy and Transurethral Water Jet Ablation (Aquablation) for Benign Prostatic Hypertrophy</b>			
<b>Original Policy Date:</b>	August 1, 2019	<b>Effective Date:</b>	August 1, 2024
<b>Section:</b>	7.0 Surgery	<b>Page:</b>	Page 1 of 18

**Policy Statement**

- I. Transurethral water vapor thermal therapy is considered **investigational** as a treatment of benign prostatic hyperplasia.
- II. Transurethral waterjet ablation (aquablation) is considered **investigational** as a treatment of benign prostatic hyperplasia.

**NOTE:** Refer to [Appendix A](#) to see the policy statement changes (if any) from the previous version.

**Policy Guidelines**

**Coding**  
See the [Codes table](#) for details.

**Description**

Transurethral water vapor thermal therapy is a minimally invasive alternative to transurethral resection of the prostate (TURP). Transurethral water vapor thermal therapy is a process by which water vapor is created outside of the body and delivered to the prostate with a needle. The procedure uses radiofrequency-generated water vapor (~103°C) thermal energy to ablate prostate tissue. The treatment is repeated in multiple locations within the prostate. During the procedure, saline irrigation cools and protects the surface of the urethra. The heat from the vapor disrupts cell membranes in the prostate, which leads to cell death and necrosis.

**Related Policies**

- N/A

**Benefit Application**

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

**Regulatory Status**

In September 2016, the Rezum™ System (NxThera, Inc, acquired by Boston Scientific in 2018) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process (K150786). The FDA determined that this device was substantially equivalent to existing devices

(Medtronic Prostiva devices). Rezum is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH. It is indicated for men >50 years of age with a prostate volume >30 cm<sup>3</sup> and <80 cm<sup>3</sup>. The Rezum System is also indicated for the treatment of prostate with hyperplasia of the central zone and/or a median lobe.

In April 2017, the Aquabeam<sup>®</sup> System (Procept Robotics Corporation) was cleared for marketing by the FDA through the 513(f)(2) (de novo) classification process (DEN170024).<sup>4</sup> The device is intended for the resection and removal of prostate tissue in males with LUTS due to BPH, based on WATER trial.

## Rationale

### Background

Benign prostatic hyperplasia (BPH) is a common condition in older men, affecting to some degree 40% of men in their 50s, 70% of those between ages 60 and 69, and almost 80% of those ages 70 and older.<sup>1</sup> BPH is a histologic diagnosis defined as an increase in the total number of stromal and glandular epithelial cells within the transition zone of the prostate gland. In some men, BPH results in prostate enlargement which can, in turn, lead to benign prostate obstruction and bladder outlet obstruction, which are often associated with lower urinary tract symptoms including urinary frequency, urgency, irregular flow, weak stream, straining, and waking up at night to urinate. Lower urinary tract symptoms is the most commonly presenting urological complaint and can have a significant impact on the quality of life.<sup>1</sup>

BPH does not necessarily require treatment. The decision on whether to treat BPH is based on an assessment of the impact of symptoms on quality of life along with the potential side effects of treatment. Options for medical treatment include alpha-1-adrenergic antagonists, 5-alpha-reductase inhibitors, anticholinergic agents, and phosphodiesterase-5 inhibitors. Medications may be used as monotherapy or in combination.<sup>2</sup>

Patients with persistent symptoms despite medical treatment may be considered for surgical treatment. The traditional standard treatment for BPH is transurethral resection of the prostate.

Transurethral water vapor thermal therapy has been investigated as a minimally invasive alternative to transurethral resection of the prostate. The procedure uses radiofrequency-generated water vapor (~103°C) thermal energy to ablate prostate tissue.<sup>3</sup>

### Literature Review

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

### **Transurethral Water Vapor Thermal Therapy Clinical Context and Therapy Purpose**

The purpose of transurethral water vapor thermal therapy in individuals who have benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest is individuals with BPH and LUTS. Symptoms include urinary frequency, urgency, irregular flow, weak stream, straining, and getting up at night to urinate.

#### ***Interventions***

The therapy being considered is transurethral water vapor thermal therapy. This procedure involves the transurethral injection of steam into the prostate. Once injected, the steam condenses to water, imparting convective energy to the tissue, causing cell death and damage. The technology uses radiofrequency to boil the water to create the steam that is injected but does not impart radiofrequency directly to the prostate tissue. Individuals typically require catheterization for at least 1 week due to post-procedure sloughing of prostatic tissue.

Medical management of pain and anxiety may also be required. In one RCT, 69% of participants received oral sedation only, 21% received a prostate block, and 10% received intravenous sedation.

#### ***Comparators***

The following practices and therapies are currently being used to make decisions about transurethral water vapor thermal therapy:

- Conservative treatment, including watchful waiting and lifestyle modifications;
- Pharmacotherapy;
- Transurethral resection of the prostate (TURP);
- Prostatic urethral lift.

#### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, quality of life, retreatment rates, and treatment-related morbidity.

The International Prostate Symptom Score (IPSS) is used to assess the severity of BPH symptoms. The first 7 questions address urinary frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency each on a scale of 0 to 5. The total score, summed across the 7 items measured, ranges from 0 (no symptoms) to 35 (most severe symptoms). A decrease in score indicates improvement.

Quality of life (QoL) is assessed with various scales including the IPSS-QoL.

Erectile and ejaculatory function is assessed in sexually active individuals only. Scales include the International Index of Erectile Function and the Male Sexual Health Questionnaire.

Both short-term (up to 12 months) and long-term (12 months and longer) outcomes should be assessed. Treatment-related morbidity can also be assessed in the immediate post-procedure period.

### Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

## Review of Evidence

### Systematic Review

Kang et al (2020) conducted a Cochrane review of transurethral water vapor thermal therapy for management of LUTS in men with BPH.<sup>5</sup> In literature searches conducted through February 2020, the reviewers identified only a single RCT (McVary et al [2015],<sup>6</sup> discussed in the section below). The reviewers concluded that there was moderate-to low-certainty evidence that the procedure appears to improve urologic symptom scores and QoL compared to a sham procedure. However, there was very low certainty of evidence about the effects of the intervention on major adverse events.

### Randomized Controlled Trial

Transurethral water vapor thermal therapy has been evaluated in a single RCT conducted in 197 men (Table 1). Three-month results were reported in McVary et al (2015).<sup>6</sup>

The trial also had an uncontrolled, open-label, crossover phase. After unblinding at 3 months, control subjects who elected to proceed were requalified for the crossover study. A total of 97 patients were followed through 3 years and 90 patients through 4 years. Three-year results were reported in McVary et al (2018)<sup>3</sup>, and 4-year results in McVary et al (2019).<sup>7</sup> These results are shown in Table 1.

**Table 1. Randomized Controlled Trial of Rezum: Characteristics**

Study; Trial	Countries	Sites	Dates	Participants	Interventions	
					Active	Comparator
McVary et al 2015, <sup>6</sup> 2018 <sup>3</sup> , 2019 <sup>7</sup> , 2021 <sup>8</sup> , NCT01912339	United States	15	2013-2016	Men with moderate to severe symptomatic BPH, at least 50 years of age (61% were under age 65 years) with IPSS $\geq 13$ , a prostate volume of 30 mL to 80 mL, Q <sub>max</sub> of $\leq 15$ mL/s, and a measured postvoid residual urine of <250 mL.	n=136 Transurethral water vapor thermal therapy (Rezum)	n=61 Sham procedure with rigid cystoscopy and activation of the system generator outside the subject's body to mimic the sound of the active procedure
				Exclusion criteria included a prostate-specific antigen >2.5 ng/mL with a free prostate specific antigen <25% (unless prostate cancer was ruled out by biopsy)		

Study; Trial	Countries	Sites	Dates	Participants	Interventions
				and an active urinary tract infection.	

BPH: benign prostatic hyperplasia; IPSS: International Prostate Symptom Score; NCT: national clinical trial; Qmax: maximum urinary flow rate.

Results of the RCT are shown in Table 2. The primary outcome was the difference in the change from baseline between the treatment and control arms at 3 months post-treatment. The secondary outcome was the percentage of responders at 3 months. Response was defined as a 30% or greater improvement (reduction) in the IPSS at 3 months compared to baseline. The Rezum group showed an 11.2-point decrease in IPSS, versus a 4.3-point decrease in the sham group ( $p < .001$ ). There were more responders (defined as 30% or more improvement in the IPSS) in the Rezum group. Notably, more than half of the patients in the control group were classified as responders at 3 months. There were significant differences in other measures of LUTS and QoL.

One hundred thirty of the 197 participants (70.0%) reported being sexually active at baseline and were assessed for erectile function. There were no significant changes in erectile or ejaculatory function at follow-up and no differences between groups. That is, the treatment was not associated with adverse effects on erectile or ejaculatory function. A *post hoc* subgroup analysis of 125 Rezum-treated subjects who were sexually active at baseline found that sexual function continued to be unimpacted at 5 years.<sup>9</sup> However, only 67 of these participants (53.6%) had follow-up data at this timepoint.

Two patients in the Rezum group experienced 3 serious procedure-related adverse events: 1 patient had de novo extended urinary retention and another had nausea and vomiting due to alprazolam and was hospitalized overnight for observation.

**Table 2. Randomized Controlled Trial of Rezum: Results**

Study	IPSS change from baseline	Responders (30% improvement in IPSS)	IPSS QoL	Qmax (mL/s)	BPHII	IIEF-EF	MSHQ-EJ function	MSHQ-EJ bother	Serious AEs
<b>McVary et al (2015)<sup>6</sup></b>									
<b>N analyzed</b>	197	197	197	194	195	130	130	130	197
<b>Rezum</b>	-11.2 (7.6)	106/136 (77.9%)	-2.1 (1.6)	6.2 (7.1)	-3.4 (3.5)	0.1 (7.4)	0.3 (4.3)	-0.4 (1.9)	66/136 (48.5%)
<b>Sham</b>	-4.3 (6.9)	21/61 (59.5%)	-0.9 (1.5)	0.5 (4.2)	-1.5 (3.0)	-1.5 (3.0)	-0.2 (3.2)	-0.2 (1.9)	4/61 (6.6%)
<b>p-value</b>	<.0001	<.0001	<.0001	<.0001	<.0003	.0003	.443	.623	NR

AE: adverse events; BPHII: benign prostatic hyperplasia Impact Index; IIEF: International Index of Erectile Function; IPSS: International Prostate Symptom Score; MSHQ-EJ: Male Sexual Health Questionnaire for Ejaculatory Dysfunction; NR: not reported; Qmax: peak urinary flow rate; QoL: quality of life.

The trial also had an uncontrolled, open-label, crossover phase, reported in McVary et al (2018), McVary et al (2019), and McVary et al (2021). After unblinding at 3 months, control subjects who elected to proceed were requalified for the crossover study. A total of 98 patients were followed through 60 months. These results are shown in Table 3. Urinary symptoms and QoL remained significantly improved from baseline up to 5 years. Over 5 years, the surgical retreatment rate was 4.4% and the medication retreatment rate was 11.1%.<sup>8</sup>

**Table 3. Randomized Controlled Trial of Rezum: Results of Open-label Uncontrolled Crossover Phase (McVary et al [2018]<sup>5</sup>, McVary et al [2019]<sup>7</sup>, and McVary et al [2021])<sup>8</sup>**

Outcome, mean change from baseline (SD)	3 months	6 months	12 months	24 months	36 months	48 months	60 months <sup>1</sup>
<b>IPSS</b>							
N	134	129	121	109	97	90	
Change	-11.3 (7.6)	-12.2 (7.6)	-11.6 (7.3)	-11.2 (7.3)	-11.0 (7.1)	-10.1 (7.6)	-11.1 (7.8)
p-value	<.0001	<.0001	<.0001	<.0001	<.0001	<.0001	
<b>IPSS QoL</b>							
N	134	129	121	109	97	90	
Change	-2.1 (1.6)	-2.3 (1.6)	-2.2 (1.6)	-2.2 (1.5)	-2.2 (1.6)	-2.0 (1.7)	-2.2 (1.4)
p-value	<.0001	<.0001	<.0001	<.0001	<.0001	<.0001	
<b>Qmax</b>							
N	125	119	112	99	80	81	
Change	6.4 (7.2)	5.7 (6.2)	5.5 (6.4)	4.8 (6.1)	3.5 (4.7)	4.2 (5.7)	4.1
p-value							
<b>PVR volume</b>							
N	133	125	118	106	92	89	
Change	-10.6 (68.3)	-8.4 (75.8)	-3.9 (82.7)	-0.3 (85.3)	-26.4 (63.9)	-9.2 (72.2)	NR
p-value	.3459	.3721	.8943	.6549	.0004		
<b>BPHII</b>							
N	143	129	121	109	97	90	
Change	-3.4 (3.5)	-4.1 (3.0)	-3.9 (3.3)	-3.8 (3.1)	-3.7 (3.3)	-3.5 (3.4)	-2.2 (1.4)
p-value	<.0001	<.0001	<.0001	<.0001	<.0001	<.0001	
<b>IIEF-EF</b>							
N	90	84	77	71	62	58	
Change	0.1 (7.4)	-0.3 (6.4)	-0.3 (7.5)	-1.2 (7.6)	-1.9 (8.2)	-2.5 (8.7)	-2.4 ± 9.2
p-value	.8927	.8816	.8709	.4080	.1119	.03333	
<b>MSHQ-EjD Function</b>							
N	90	83	78	70	63	56	
change	0.3 (4.3)	0.1 (3.6)	-0.3 (3.5)	-0.5 (4.2)	-1.4 (3.8)	-1.8 (4.4)	NR
p-value	.5612	.7451	.2778	.3505	.0033	.0038	
<b>MSHQ-EjD Bother</b>							
N	90	84	79	70	63	56	
change	-0.3 (1.9)	-0.4 (1.9)	-0.7 (1.8)	-0.5 (1.7)	-0.5 (1.6)	-0.1 (1.8)	NR
p-value	.776	.951	.0015	.0129	.0060	.6495	

<sup>1</sup>Some outcomes were presented graphically only and did not include number analyzed, P-values, or change from baseline.

BPHII: Benign Prostatic Hyperplasia Impact Index; IIEF-EF: International Index of Erectile Function; IPSS: International Prostate Symptom Score; MSHQ-EjD: Male Sexual Health Questionnaire for Ejaculatory Dysfunction; NR: not reported; PVR: postvoid residual urine volume; Qmax: peak urinary flow rate; QoL: quality of life; SD: standard deviation.

Notable relevance and study design and conduct limitations of the RCT reported by McVary et al are summarized in Tables 4 and 5. The major limitations were the short follow-up duration in the sham-controlled phase, and lack of blinding, no control group, and high loss to follow-up in the follow-up phase. Additionally, no studies have compared Rezum to medical management, TURP, or other minimally invasive procedures. Because LUTS in men with BPH may improve spontaneously over time, it is important for future studies to include a longer follow-up period with a control group.

**Table 4. Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Follow-Up <sup>e</sup>
McVary et al (2015) <sup>6</sup>			Sham procedure; no comparison to alternative treatments	Clinically significant difference on symptoms not prespecified	1, 2: 3 months
McVary et al (2018) <sup>3</sup> , McVary et al (2019) <sup>7</sup> , and McVary et al (2021) <sup>8</sup>			No control group (comparison to baseline only)	Clinically significant difference in symptom outcomes not prespecified	

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

**Table 5. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Data Completeness <sup>d</sup>	Power <sup>e</sup>	Statistical Reporting <sup>f</sup>
McVary et al (2015) <sup>6</sup>						
McVary et al (2018) <sup>3</sup> , McVary et al (2019) <sup>7</sup> , and McVary et al (2021) <sup>8</sup>		1, 2, 3: open label		High loss to follow-up (97/197 [49%] had 3-year data on primary outcome), 90/197 (46%) had 4-year data), 98/197 (50%) had 5-year data		

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

### Section Summary: Transurethral Water Vapor Thermal Therapy

Rezum effectively reduced symptoms of BPH compared to sham treatment in one RCT with 5 years of follow-up; however, comparisons to TURP or other active therapies are lacking.

## **Transurethral Waterjet Ablation (Aquablation)**

### **Clinical Context and Therapy Purpose**

The purpose of aquablation in individuals who have BPH and LUTS is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with BPH and LUTS. Symptoms include urinary frequency, urgency, irregular flow, weak stream, straining, and getting up at night to urinate.

### ***Interventions***

The therapy being considered is transurethral waterjet ablation, known as aquablation. Aquablation cuts tissue by using a pressurized jet of fluid delivered to the prostatic urethra. The device is able to image the treatment area, or pairs with an imaging modality, to monitor treatment progress.

### ***Comparators***

The following practices and therapies are currently being used to make decisions about aquablation:

- Conservative treatment, including watchful waiting and lifestyle modifications;
- Pharmacotherapy;
- TURP;
- Prostatic urethral lift.

### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, quality of life, retreatment rates, and treatment-related morbidity.

The IPSS is used to assess the severity of BPH symptoms. The first 7 questions address urinary frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency each on a scale of 0 to 5. The total score, summed across the 7 items measured, ranges from 0 (no symptoms) to 35 (most severe symptoms). A decrease in score indicates improvement. Quality of life is assessed with various scales including the IPSS-QoL.

Erectile and ejaculatory function is assessed in sexually active individuals only. Scales include the International Index of Erectile Function and the Male Sexual Health Questionnaire.

Both short-term (up to 12 months) and long-term (12 months and longer) outcomes should be assessed. Treatment-related morbidity can also be assessed in the immediate post-procedure period.

### ***Study Selection Criteria***

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

## **Review of Evidence**

### **Systematic Review**

Elterman et al (2021) performed a meta-analysis of individual patient data from 4 prospective, multicenter trials (N=425) with aquablation in the management of symptomatic BPH (Tables 6 to 8).<sup>10</sup> The 4 studies were WATER (an RCT), WATER II (a prospective single-arm study), OPEN WATER (a



prospective single-arm study), and FRANCAIS WATER (an observational study). Each study had at least 1 year of follow-up. Pooled results from all 4 studies showed improvement from baseline in IPSS, IPSS-QoL, maximum urine flow rate, and postvoid residual volume. There were no new cases of erectile dysfunction postoperatively, but 10.8% of men reported new ejaculatory dysfunction.

**Table 6. Comparison of Trials/Studies Included in Systematic Review and Meta-Analysis**

	Elterman et al (2021) <sup>10</sup> ,
Gilling et al (2019) <sup>11</sup> ; WATER	

Trial	Countries	Sites	Dates	Participants	Interventions
<b>WATER<sup>11,16,17</sup>, NCT02505919</b>	US, UK, Australia, New Zealand	17	October 2015- December 2016	Men age 45 to 80 years with a prostate size between 30 to 80 mL, moderate-to severe LUTS (IPSS 10 to $\geq$ 12), and Qmax <15 mL/s.	Aquablation n=65 TURP n=116

IPSS: International Prostate Symptom Score; LUTS: lower urinary tract symptoms; Qmax: peak urinary flow rate; TURP: transurethral resection of the prostate; WATER: Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue.

WATER trial results at 12 months, as summarized in the Cochrane review, are shown in Table 10. The reviewers assessed the certainty of the evidence for each outcome using the GRADE approach.<sup>18</sup> The reviewers concluded that up to 12 months, aquablation likely results in a similar improvement in urologic symptom scores to TURP and may result in similar quality of life when compared to TURP. The authors also concluded that aquablation may result in little to no difference in major adverse events, but considered the evidence for this finding very low certainty due to study limitations and imprecision of estimates.

**Table 10. WATER Trial Results at 12 months (Adapted from Hwang et al [2019]<sup>18</sup>)**

Outcome at 12 months	N Analyzed	Mean Difference (95% CI)	Certainty of the Evidence (Reason for downgrading)
<b>IPSS</b>	174	-0.6 (-2.51 to 2.39)	Moderate (study limitations)
<b>IPSS QoL</b>	174	0.27 (-0.024 to 0.78)	Low (imprecision)
<b>Major adverse events</b>	181	15 fewer per 1000 (-64 to 116) RR 0.84 (0.31 to 2.26)	Very low (high risk of performance bias, unclear risk of reporting bias, wide CI crosses assumed threshold of minimal clinically important difference)
<b>Retreatment</b>	181	10 more per 1000 (13 fewer to 228 more) RR 1.68 (0.18 to 15.83)	Very low (imprecision and high risk of performance and attrition bias)
<b>Erectile function</b>	64	2.31 (-0.63 to 5.25)	Very low (imprecision and high risk of performance and attrition bias)
<b>Ejaculatory function</b>	121	2.57 (0.6 to 4.53)	Very low (imprecision: CI crosses assumed threshold of minimal clinically important difference, high risk of performance and attrition bias)

Source: adapted from Hwang et al (2019)<sup>18</sup>.

CI: confidence interval; IPSS: International Prostate Symptom Score; QoL: quality of life; RR: relative risk; WATER: Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue.

Gilling et al (2020) and Gilling et al (2022) reported WATER trial results at 3 and 5 years, respectively (Table 11).<sup>16,17</sup> Improvements in symptoms and quality of life were maintained through 3 years in both treatment groups, and the rate of serious adverse events did not differ between groups any any time

point. Efficacy was maintained through 5 years as well, but safety results were not reported beyond 3 years.

**Table 11. WATER Trial Results at 3 and 5 Years**

Study	Mean IPSS reduction	Mean % reduction in IPSS	Improvement at least 5 points from baseline	IPSS QoL improvement	Qmax (mL/s)	Retreatm ent Rate	Serious AEs Subjects (%)
<b>WATER<sup>16,17</sup>, NCT02505919</b>							
<b>3 year results</b>							
Aquablation	14.4 (6.8)	64%	78%	3.2 (1.8)	11.6	5/116 (4.3%)	0 to 3 months: 7 (6.0%) 3 months to 1 year: 5 (4.3%) 1 to 2 years: 8 (6.9%) 2 to 3 years: 4 (3.4%)
TURP	13.9 (8.6)	61%	82%	3.2 (1.7)	8.2	1/65 (1.5%)	0 to 3 months: 4 (6.2%) 3 months to 1 year: 5 (7.7%) 1 to 2 years: 2 (3.1%) 2 to 3 years: 1 (1.5%)
<b>Difference</b>	0.6 (-3.3 to 2.2)	3%	4%	0	3.3 (-0.5 to 7.1)	2.8%	
<b>p-value</b>	.6848	NS	NS	.7845	.0848	.4219	NS at any time point
<b>5 year results</b>							
Aquablation	15.1 (6.6)	NR	NR	NR	8.7 (9.1)	6.0%	NR
TURP	13.2 (8.2)	NR	NR	NR	6.3 (7.5)	12.3%	NR
<b>Difference</b>	1.9	NR	NR	NR	NR	6.3%	NR
<b>p-value</b>	.2764	NR	NR	NR	NR	NR	NR

AE: adverse events; IPSS: International Prostate Symptom Score; NR: not reported; NS: not significant; Qmax: peak urinary flow rate; QoL: quality of life; TURP: transurethral resection of the prostate; WATER: Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue.

Study design and conduct limitations of the WATER trial are displayed in Tables 12 and 13. Limitations included a lack of blinding of treating clinicians and baseline evaluators, but blinding of study participants makes this less of a concern. Adverse events were adjudicated up to 1 year, but not after 1 year.

**Table 12. Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Follow-Up <sup>e</sup>
<b>WATER<sup>11,16,17</sup>, NCT02505919</b>					
				Adverse events occurring after month 12 were not adjudicated by the clinical events committee	

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

**Table 13. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Data Completeness <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
WATER <sup>11,16,17</sup> NCT02505919		Baseline evaluation and study surgeons were not blinded; patients and outcome assessors were blinded	Unclear - secondary outcomes not prespecified			

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

### Section Summary: Transurethral Waterjet Ablation (Aquablation)

Aquablation was compared to TURP in the WATER trial, with follow-up until 5 years. Aquablation was superior to TURP for the primary safety endpoint at 6 months, but few safety results beyond 6 months are available. At 3 years and 5 years, there were no significant differences between groups in IPSS scores.

### Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to

guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### American Urological Association

In 2021, the American Urological Association published guidelines on the surgical evaluation and treatment of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH).<sup>19</sup> An amendment to these guidelines was published in 2023.<sup>20</sup> The following recommendations are related to the interventions included in this evidence review:

- Water vapor thermal therapy should be considered as a treatment option for patients with LUTS/BPH provided prostate volume is 30 to 80 g. (Moderate Recommendation; Evidence Level: Grade C)
- Water vapor thermal therapy may be offered as a treatment option to eligible patients who desire preservation of erectile and ejaculatory function. (Conditional Recommendation; Evidence Level: Grade C)
- Robotic waterjet treatment may be offered as a treatment option to patients with LUTS/BPH provided prostate volume is 30 to 80 g. (Conditional Recommendation; Evidence Level: Grade C)

### National Institute for Health and Care Excellence

In 2020, the NICE issued the following guidance on Rezum for treatment of LUTS secondary to BPH:<sup>21</sup> "Evidence supports the case for adopting Rezum for treating lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) in the NHS [National Health Service]. Rezum relieves LUTS and improves quality of life."

"Rezum is a minimally invasive procedure. It should be considered as a treatment option for people with:

- moderate to severe LUTS (International Prostate Symptoms Score [IPSS] typically 13 or over) and
- a moderately enlarged prostate (typically between 30 cm<sup>3</sup> and 80 cm<sup>3</sup>)."

In 2023, NICE updated guidance on transurethral water jet ablation for LUTS caused by BPH.<sup>22</sup> The following recommendations were made:

"Transurethral water-jet ablation for lower urinary tract symptoms caused by BPH may be used if standard arrangements are in place for clinical governance, consent, and audit. For auditing the outcomes of this procedure, the main efficacy and safety outcomes identified in this guidance can be entered into NICE's interventional procedure outcomes audit tool (for use at local discretion)."

A Medtech innovation briefing was released by NICE in January 2023 but guidance specific to Aquablation is awaiting development.<sup>23</sup>

### U.S. Preventive Services Task Force Recommendations

Not applicable.

### Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

### Ongoing and Unpublished Clinical Trials

Ongoing trials that might influence this review are listed in Table 14.

**Table 14. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT04838769 <sup>a</sup>	Water Vapor Thermotherapy vs. Combination Pharmacotherapy for Symptomatic Benign Prostatic	394	Jul 2026

NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT05762198	Hyperplasia Refractory to Alpha Blocker Monotherapy in Sexually Active Men: A Multicenter Randomized Controlled Trial A Randomized Controlled Trial Comparing Water Vapour Thermal Therapy (Rezūm) and TURP in Men With Benign Prostatic Hyperplasia in Refractory Urinary Retention	108	Jun 2026
NCT04338776 <sup>a</sup>	C.L.E.A.R. - Comparing UroLift Experience Against Rezum	120	May 2025
NCT04801381	WATER III: A Randomized, Controlled Trial of Aquablation vs. Transurethral Laser Enucleation of Large Prostates (80 - 180 mL) in Benign Prostatic Hyperplasia	200	Dec 2028

<sup>a</sup>Denotes industry sponsored or cosponsored trial

NCT: National Clinical Trial

## References

- UpToDate. Medical treatment of benign prostatic hyperplasia. Updated January 2024. Available at: [https://www.uptodate.com/contents/medical-treatment-of-benign-prostatic-hyperplasia?search=benign%20prostatic%20hyperplasia&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1](https://www.uptodate.com/contents/medical-treatment-of-benign-prostatic-hyperplasia?search=benign%20prostatic%20hyperplasia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1). Accessed April 17, 2024.
- Westwood J, Geraghty R, Jones P, et al. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. *Ther Adv Urol*. Nov 2018; 10(11): 327-333. PMID 30344644
- McVary KT, Roehrborn CG. Three-Year Outcomes of the Prospective, Randomized Controlled Rezūm System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. *Urology*. Jan 2018; 111: 1-9. PMID 29122620
- Food and Drug Administration (2017). Aquabeam System Device Classification Under Section 513(f)(2)(De Novo). <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm?ID=DEN170024>. Accessed April 17, 2024.
- Kang TW, Jung JH, Hwang EC, et al. Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev*. Mar 25 2020; 3(3): CD013251. PMID 32212174
- McVary KT, Gange SN, Gittelman MC, et al. Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *J Urol*. May 2016; 195(5): 1529-1538. PMID 26614889
- McVary KT, Rogers T, Roehrborn CG. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. *Urology*. Apr 2019; 126: 171-179. PMID 30677455
- McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *J Urol*. Sep 2021; 206(3): 715-724. PMID 33872051
- McVary KT, El-Arabi A, Roehrborn C. Preservation of Sexual Function 5 Years After Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia. *Sex Med*. Dec 2021; 9(6): 100454. PMID 34731779
- Elterman D, Gillig P, Roehrborn C, et al. Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies. *BMJ Surg Interv Health Technol*. 2021; 3(1): e000090. PMID 35047807
- Gilling P, Barber N, Bidair M, et al. WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. *J Urol*. May 2018; 199(5): 1252-1261. PMID 29360529

12. Bhojani N, Bidair M, Kramolowsky E, et al. Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results. *J Urol*. Jul 2023; 210(1): 143-153. PMID 37115632
13. Misrai V, Rijo E, Zorn KC, et al. Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction in Patients with Small- to Medium-size Glands: 12-month Results of the First French Aquablation Clinical Registry. *Eur Urol*. Nov 2019; 76(5): 667-675. PMID 31281024
14. Bach T, Gilling P, El Hajj A, et al. First Multi-Center All-Comers Study for the Aquablation Procedure. *J Clin Med*. Feb 24 2020; 9(2). PMID 32102329
15. Gilling PJ, Barber N, Bidair M, et al. Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes. *Urology*. Mar 2019; 125: 169-173. PMID 30552937
16. Gilling P, Barber N, Bidair M, et al. Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. *Can J Urol*. Feb 2020; 27(1): 10072-10079. PMID 32065861
17. Gilling PJ, Barber N, Bidair M, et al. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. *Can J Urol*. Feb 2022; 29(1): 10960-10968. PMID 35150215
18. Hwang EC, Jung JH, Borofsky M, et al. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev*. Feb 13 2019; 2(2): CD013143. PMID 30759311
19. Lerner LB, McVary KT, Barry MJ, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment. *J Urol*. Oct 2021; 206(4): 818-826. PMID 34384236
20. Sandhu JS, Bixler BR, Dahm P, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. *J Urol*. Jan 2024; 211(1): 11-19. PMID 37706750
21. National Institute for Health and Care Excellence (2020). Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. <https://www.nice.org.uk/guidance/mtg49/chapter/1-Recommendations>. Accessed April 16, 2024.
22. National Institute for Health and Care Excellence (2023). Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. [IPG770]. <https://www.nice.org.uk/guidance/ipg770>. Accessed April 17, 2024.
23. National Institute for Health and Care Excellence (NICE). Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia. January 1, 2023. <https://www.nice.org.uk/advice/mib315/chapter/Clinical-and-technical-evidence>. Accessed April 15, 2024.

## Documentation for Clinical Review

- No records required

## Coding

*This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.*

*The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.*

Type	Code	Description
CPT®	0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance
	53854	Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy
	55899	Unlisted procedure, male genital system
HCPCS	C2596	Probe, image guided, robotic, waterjet ablation

## Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

Effective Date	Action
08/01/2019	BCBSA Medical Policy adoption
03/01/2020	Coding update
08/01/2023	Policy reactivated. Previously archived from 07/01/2020 to 07/31/2023.
08/01/2024	Annual review. No change to policy statement. Policy guidelines and literature review updated.

## Definitions of Decision Determinations

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member's illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

## Prior Authorization Requirements and Feedback (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.



Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at [www.blueshieldca.com/provider](http://www.blueshieldca.com/provider).

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: [MedPolicy@blueshieldca.com](mailto:MedPolicy@blueshieldca.com)

*Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.*

**Appendix A**

POLICY STATEMENT (No changes)	
BEFORE	AFTER
<p>Transurethral Water Vapor Thermal Therapy and Transurethral Water Jet Ablation (Aquablation) for Benign Prostatic Hypertrophy 2.01.49</p> <p><b>Policy Statement:</b></p> <ul style="list-style-type: none"> <li>I. Transurethral water vapor thermal therapy is considered <b>investigational</b> as a treatment of benign prostatic hyperplasia.</li> <li>II. Transurethral waterjet ablation (aquablation) is considered <b>investigational</b> as a treatment of benign prostatic hyperplasia.</li> </ul>	<p>Transurethral Water Vapor Thermal Therapy and Transurethral Water Jet Ablation (Aquablation) for Benign Prostatic Hypertrophy 2.01.49</p> <p><b>Policy Statement:</b></p> <ul style="list-style-type: none"> <li>I. Transurethral water vapor thermal therapy is considered <b>investigational</b> as a treatment of benign prostatic hyperplasia.</li> <li>II. Transurethral waterjet ablation (aquablation) is considered <b>investigational</b> as a treatment of benign prostatic hyperplasia.</li> </ul>